Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Anaptysbio (ANAB) Invested Capital (2016 - 2025)

Anaptysbio (ANAB) has disclosed Invested Capital for 10 consecutive years, with $37.2 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Invested Capital fell 47.49% year-over-year to $37.2 million, compared with a TTM value of $37.2 million through Dec 2025, down 47.49%, and an annual FY2025 reading of $37.2 million, down 47.49% over the prior year.
  • Invested Capital was $37.2 million for Q4 2025 at Anaptysbio, up from -$29.4 million in the prior quarter.
  • Across five years, Invested Capital topped out at $385.7 million in Q2 2021 and bottomed at -$44.7 million in Q2 2025.
  • Average Invested Capital over 5 years is $172.0 million, with a median of $134.4 million recorded in 2023.
  • The sharpest move saw Invested Capital increased 6.49% in 2021, then tumbled 552.81% in 2025.
  • Year by year, Invested Capital stood at $356.4 million in 2021, then decreased by 26.46% to $262.1 million in 2022, then tumbled by 66.39% to $88.1 million in 2023, then dropped by 19.56% to $70.9 million in 2024, then plummeted by 47.49% to $37.2 million in 2025.
  • Business Quant data shows Invested Capital for ANAB at $37.2 million in Q4 2025, -$29.4 million in Q3 2025, and -$44.7 million in Q2 2025.